Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Clin Drug Investig ; 42(8): 703, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35788977
2.
Clin Drug Investig ; 42(Suppl 1): 1-2, 2022 06.
Article in English | MEDLINE | ID: mdl-35532834
3.
Clin Drug Investig ; 42(Suppl 1): 3, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35616885
4.
Rev. esp. enferm. dig ; 114(4): 219-225, abril 2022. tab, graf
Article in English | IBECS | ID: ibc-205600

ABSTRACT

Introduction: despite advances in imaging diagnosticmodalities, hepatocellular carcinoma is sometimes incidentally diagnosed on histological examination of the liver explant. The objectives of the study were: a) to compare the characteristics between incidental and known hepatocellular carcinoma; and b) to estimate survival and tumor recurrence after liver transplantation.Material and methods: a retrospective, single-center study was performed. The inclusion criteria were: a) cirrhotic patients, age ≥ 18 years; b) liver transplantation between 1998 and 2018; and c) hepatocellular carcinoma diagnosed via histopathologic examination of the explanted liver. Cholangiocarcinoma and patients with early retransplantation were excluded. Multivariate analysis was performed using binomial logistic regression to assess the factors associated with incidental hepatocellular carcinoma. Kaplan-Meier curves were plotted to explore the impact on overall survival and recurrence free survival.Results: two hundred and sixty-nine patients were enrolled. The prevalence of incidental hepatocellular carcinoma was 4.18 % (95 % CI: 2.89-6.01 %) of all liver transplants performed in cirrhotic patients. The median diameter of the main nodule was smaller in incidental hepatocellular carcinoma (20 vs 27 mm, p = 0.004), although they were more likely to be beyond the Up-to-Seven criteria on explant examination (22.2 % vs 7.5 %, p = 0.001), with no differences in any other histological features. No differences were found in overall survival rates (incidental 70.2 % vs 70.4 %, p = 0.87) or recurrence-free survival (incidental 100 % vs 83.8 %, p = 0.07) at five years. Conclusion: incidental hepatocellular carcinoma are smaller in size and are more frequently found to be beyond the Up-to-Seven criteria. However, no differences were found in overall survival rates or recurrence-free survival, although there was no tumor recurrence in the incidental hepatocellular carcinoma group. (AU)


Subject(s)
Humans , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/surgery , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/epidemiology , Liver Neoplasms/surgery , Treatment Outcome , Kaplan-Meier Estimate , Liver Transplantation , Retrospective Studies
5.
Rev Esp Enferm Dig ; 114(4): 219-225, 2022 04.
Article in English | MEDLINE | ID: mdl-33733806

ABSTRACT

INTRODUCTION: despite advances in imaging diagnostic modalities, hepatocellular carcinoma is sometimes incidentally diagnosed on histological examination of the liver explant. The objectives of the study were: a) to compare the characteristics between incidental and known hepatocellular carcinoma; and b) to estimate survival and tumor recurrence after liver transplantation. MATERIAL AND METHODS: a retrospective, single-center study was performed. The inclusion criteria were: a) cirrhotic patients, age ≥ 18 years; b) liver transplantation between 1998 and 2018; and c) hepatocellular carcinoma diagnosed via histopathologic examination of the explanted liver. Cholangiocarcinoma and patients with early retransplantation were excluded. Multivariate analysis was performed using binomial logistic regression to assess the factors associated with incidental hepatocellular carcinoma. Kaplan-Meier curves were plotted to explore the impact on overall survival and recurrence free survival. RESULTS: two hundred and sixty-nine patients were enrolled. The prevalence of incidental hepatocellular carcinoma was 4.18 % (95 % CI: 2.89-6.01 %) of all liver transplants performed in cirrhotic patients. The median diameter of the main nodule was smaller in incidental hepatocellular carcinoma (20 vs 27 mm, p = 0.004), although they were more likely to be beyond the Up-to-Seven criteria on explant examination (22.2 % vs 7.5 %, p = 0.001), with no differences in any other histological features. No differences were found in overall survival rates (incidental 70.2 % vs 70.4 %, p = 0.87) or recurrence-free survival (incidental 100 % vs 83.8 %, p = 0.07) at five years. CONCLUSION: incidental hepatocellular carcinoma are smaller in size and are more frequently found to be beyond the Up-to-Seven criteria. However, no differences were found in overall survival rates or recurrence-free survival, although there was no tumor recurrence in the incidental hepatocellular carcinoma group.


Subject(s)
Bile Duct Neoplasms , Carcinoma, Hepatocellular , Liver Neoplasms , Liver Transplantation , Adolescent , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/surgery , Cohort Studies , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/epidemiology , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/pathology , Retrospective Studies , Treatment Outcome
8.
World J Gastroenterol ; 17(12): 1538-42, 2011 Mar 28.
Article in English | MEDLINE | ID: mdl-21472117

ABSTRACT

Occult hepatitis B virus (HBV) infection (OBI) is characterized by the persistence of HBV DNA in the liver tissue in individuals negative for the HBV surface antigen. The prevalence of OBI is quite variable depending on the level of endemic disease in different parts of the world, the different assays utilized in the studies, and the different populations studied. Many studies have been carried out on OBI prevalence in different areas of the world and categories of individuals. The studies show that OBI prevalence seems to be higher among subjects at high risk for HBV infection and with liver disease than among individuals at low risk of infection and without liver disease.


Subject(s)
Hepatitis B virus/pathogenicity , Hepatitis B/epidemiology , Liver/virology , Biomarkers/blood , DNA, Viral/blood , Hepatitis B/diagnosis , Hepatitis B/therapy , Hepatitis B/virology , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/growth & development , Hepatitis B virus/immunology , Hepatitis C Antibodies/blood , Humans , Prevalence , Risk Assessment , Risk Factors , Virus Activation , Virus Replication
9.
Gastroenterol Hepatol ; 31(4): 225-8, 2008 Apr.
Article in Spanish | MEDLINE | ID: mdl-18405488

ABSTRACT

Acute intermittent porphyria is an autosomal dominant inherited disorder resulting from a deficiency of porphobilinogen deaminase activity, the third enzyme in the heme biosynthesis pathway. This disease is uncommon, although the prevalence is higher in asymptomatic heterozygotic carriers; however, this prevalence is difficult to establish because of the absence of symptoms. Although acute intermittent porphyria is a multisystemic disease, its most common form of presentation is abdominal pain and neurological or mental symptoms, which can sometimes be due to precipitating factors such as reduced energy intake, smoking, alcohol, some drugs, and stress. Diagnosis can be made by testing urinary porphobilinogen levels, with subsequent measurement of enzyme activity and DNA testing. Treatment is based on prevention of porphyria attacks by avoiding precipitating factors and early administration of intravenous glucose or hemin therapy. We present the case of a patient diagnosed with acute intermittent porphyria based on study of chronic mild alanine aminotransferase (ALT) elevation.


Subject(s)
Alanine Transaminase/blood , Porphyria, Acute Intermittent/enzymology , Abdominal Pain/etiology , Erythrocytes/enzymology , Exons/genetics , Female , Heterozygote , Humans , Hydroxymethylbilane Synthase/genetics , Middle Aged , Mutagenesis, Insertional , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/diagnosis , Porphyria, Acute Intermittent/genetics
10.
Gastroenterol. hepatol. (Ed. impr.) ; 31(4): 225-228, abr.2008. ilus, tab
Article in Es | IBECS | ID: ibc-64748

ABSTRACT

La porfiria aguda intermitente es un trastorno hereditario autosómico dominante producido por un déficit en la actividad enzimática de la porfobilinógeno deaminasa, la tercera enzima en la síntesis del hemo. Se trata de una enfermedad rara, aunque los portadores heterocigotos asintomáticos tienen una prevalencia mayor, difícil de establecer dada la ausencia de clínica. Aunque la porfiria aguda intermitente es una enfermedad multisistémica, su presentación más frecuente es el dolor abdominal y los síntomas neurológicos o psiquiátricos, a veces debidos a algunos factores precipitantes, como la baja ingesta energética, el tabaco, el alcohol, algunos fármacos y el estrés. El diagnóstico se puede realizar midiendo el nivel de porfobilinógeno urinario, con posterior análisis de la actividad de la enzima defectuosa y estudio del ADN. El tratamiento se basa en la prevención de los ataques de porfiria, evitando los factores desencadenantes, y en la administración precoz de glucosa i.v. o tratamiento con hematina. Presentamos el caso de una paciente diagnosticada de porfiria aguda intermitente a partir del estudio de una elevación crónica leve de la GPT


Acute intermittent porphyria is an autosomal dominant inherited disorder resulting from a deficiency of porphobilinogen deaminase activity, the third enzyme in the heme biosynthesis pathway. This disease is uncommon, although the prevalence is higher in asymptomatic heterozygotic carriers; however, this prevalence is difficult to establish because of the absence of symptoms. Although acute intermittent porphyria is a multisystemic disease, its most common form of presentation is abdominal pain and neurological or mental symptoms, which can sometimes be due to precipitating factors such as reduced energy intake, smoking, alcohol, some drugs, and stress. Diagnosis can be made by testing urinary porphobilinogen levels, with subsequent measurement of enzyme activity and DNA testing. Treatment is based on prevention of porphyria attacks by avoiding precipitating factors and early administration of intravenous glucose or hemin therapy. We present the case of a patient diagnosed with acute intermittent porphyria based on study of chronic mild alanine aminotransferase (ALT) elevation


Subject(s)
Humans , Female , Middle Aged , Porphyria, Acute Intermittent/diagnosis , Transaminases , Hydroxymethylbilane Synthase , Abdominal Pain/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...